Previous studies indicated that suppression of HDAC2 activity by small-molecule therapeutics might display beneficial effects in the improvement of neurocognitive function [42,43] and the amelioration of AD pathologies [44], such as the removal of amyloid plaque burden [45] and the attenuation of Tau pathologies [46]. The gene discussed is HDAC2; the disease is Alzheimer disease.